Aerocrine Publishes New Issue Prospectus

​SOLNA, Sweden – 22 September 2010 - Aerocrine AB (OMX Nordic Exchange: AERO B) today announces the publication of the prospectus for the Company´s rights issue of approximately SEK 155.5 million and the directed issue of new shares and convertible bonds of SEK 225 million to Novo A/S.  The prospectus, available in Swedish language only, has been approved by and registered with the Swedish Financial Supervisory Authority (Finansinspektionen).

The prospectus is available on Aerocrine´s website, www.aerocrine.com/sv/, and on Swedbank´s website, www.swedbank.se/prospekt.  A hard copy of the prospectus can be obtained from Aerocrine free of charge, telephone: +46 8 629 07 80, and from Swedbank, telephone: +46 8 585 918 00 and e-mail: emissioner.sthlm@swedbank.se.

The prospectus will be distributed to all shareholders directly registered in Sweden. Shareholders registered through a nominee should contact their portfolio manager.

Aerocrine will shortly convene an extraordinary general meeting where it will be proposed that Scott Beardsley, a senior partner with Novo Growth Equity, is elected new member of Aerocrines’ board. In conjunction therewith, Lars Gatenbeck will leave the board.

For more information, contact: 

Paul de Potocki, CEO, telephone: +46 8 629 07 80

Michael Colérus, CFO, telephone: +46 8 629 07 85

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. The pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX® Flex. Both products enable the fast and reliable measurement of airway inflammation and may thus play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00 am on 22 September 2010.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States, Canada, South Africa, Australia, New Zeeland, Singapore, Hong Kong or Japan

IMPORTANT INFORMATION

In certain jurisdictions, publication or distribution of this press release may be subject to legal restrictions and persons in those jurisdictions where this press release has been published or distributed should inform themselves about and abide by such legal restrictions.

This press release may not be made public, published or distributed, directly or indirectly, in or into the United States, Canada, South Africa, Australia, New Zeeland, Singapore, Hong Kong, Japan or in any other country where such action is subject in full or in part to legal restrictions, nor may the information in this press release be forwarded, reproduced or disclosed in any way that is in conflict with such restrictions. Failure to follow this instruction may involve a breach of the United States Securities Act of 1933 ("Securities Act") or applicable laws in other jurisdictions.

This press release does not contain or constitute an invitation or offer to acquire, subscribe for or otherwise trade in shares, subscription rights or other securities in Aerocrine. The invitation to the persons concerned to subscribe for shares in Aerocrine will only be made through the prospectus that Aerocrine publish in September 2010, which prospectus, among other things, will contain financial statements and information on the board of directors and auditor of Aerocrine.

Neither the subscription rights, the paid subscription shares (BTA) or the new shares will be registered in accordance with the Securities Act or any provincial act in Canada, and may not be transferred or offered for sale in the United States or Canada, or to persons resident there, or on behalf of such persons, other than in such exceptional cases where registration in accordance with the Securities Act or any provincial act in Canada is not required.